Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ty MT
Hi MT ,it's nice to be back.I couldn't stay out very long cuz i missed the rush .
I 'm out of PTSC .735
XSNX -It looks that way but the volume is very not convincing maybe just dead cat bounce i'll be a buyer under 1 tho.
Hi NWO,she did try if i did't start to produce some $$$,lol.
I'm back in PTSC .65 ..way oversold.IMO
I was planning to take some time off but the gambling habit got the best of me .
I'm in NMKT .44
NewMarket Technology, Inc. Increases 2006 Revenue Forecast by 30% to $65 Million Versus $50.1 Million 2005 Annual Revenue with Net Profit of $2.9 Million
Business Wire - May 18, 2006 11:48
2006 Annual Revenue Forecast Exceeded by 17% With First Quarter Financial Results of $17.2 Million in Revenue with 326% Net Profit Increase over Same Period Last Year
DALLAS, May 18, 2006 (BUSINESS WIRE) -- NewMarket Technology Inc. (OTCBB:NMKT) released a letter today to shareholders providing an overview of the Company's first quarter operational results and announcing an increase in the 2006 revenue forecast of 30% to a profitable $65 million compared to the $50.1 million in annual revenue reported with a net profit of $2.9 million in 2005. NewMarket had previously forecasted a 15% increase in revenue in 2006 over 2005. As previously announced, management will update its revenue forecast as financial quarter results are released. After reporting $17.2 million in revenue in the first quarter of 2006 with a 326% increase in profit over the same period last year, management has doubled the forecasted increase over 2005 to 30%.
The following letter to shareholders from Philip Verges, CEO of NewMarket, provides an overview of first quarter operations and an outlook for the remainder of 2006. Philip Verges and Philip J. Rauch, CFO of NewMarket, will also conduct an audio webcast and PowerPoint presentation on Monday May 22, 2006, at 4:05 p.m. EDT to allow shareholders the opportunity to hear management discuss the Company's quarterly operational results and outlook for 2006 in more detail. The call is being webcast by Vcall and can be accessed at NewMarket Technology's website at www.newmarkettechnology.com. Investors can also access the webcast at http://www.vcall.com/IC/CEPage.asp?ID=105062. The webcast will be archived and available on the NewMarket website for replay for three months.
Dear Fellow Shareholders:
No doubt most, if not all, are disappointed in the week's stock price performance following the release of the Company's financial results for the first quarter of 2006. The Company exceeded its annual revenue forecast by 17% and increased its net profit by 326% over the same period last year, yet the share price dropped. The week has not been good for the U.S. financial markets overall. NewMarket's share price decline was likely more of a reaction to a technical filing hiccup than a reaction to overall market conditions. However, we believe that our good financial results will be appreciated in the markets going forward.
1st Quarter Financial Report Hiccup
The financial report for the first quarter filed on Form 10-Q is the Company's first report since surpassing the requirements to file as a small business. Previous quarterly financial reports were filed on Form 10QSB. On Monday, NewMarket's financial report for first quarter 2006 was inadvertently filed as a Form 10QSB, in addition to other formatting errors. To ensure NewMarket was not penalized for late filings due to the error of filing the Form 10QSB, the Company filed for an extension on Form 12b-25. The correct Form 10-Q was subsequently filed and is currently available for review at www.sec.gov. We have requested that the SEC withdraw the Form 10QSB from NewMarket's filings. NewMarket is currently in full compliance with its first quarter financial filing requirements for 2006.
Continuing Fundamental Financial Performance and Sustained Growth
The financial results for the first quarter have been previously released and are again summarized below for your review. Perhaps subtle, but nonetheless notable, the Company had a negligible cash flow increase from investing activities, yet we invested over $400,000 in subsidiary technology companies. This is a significant demonstration of NewMarket's improving fundamental financial performance and sustained growth. The Company is demonstrating an ability to support existing emerging technology investment requirements without further leveraging NewMarket stock to access investment.
-- Revenue increased 70% in Q106 to $17.3m compared to $10.2m in Q105
-- Gross profit increased 8% in Q106 to $5.1m compared to $4.7m in Q105
-- Operating expense decreased to 25% of sales in Q106 compared to 47% of sales in Q105
-- Net income (before currency translation) increased 326% in Q106 to $434k compared to $102k in Q105
-- Net income (after currency translation) increased 466% in Q106 to $577k compared to $102k in Q105
-- Accounts receivable decreased 23% since the end of 2005 from $15.1m to $11.5m at then end of Q106
-- Stockholder's equity increased 11% since the end of 2005 from $32.8m to $36.2m at the end of Q106
-- The Company's profitable revenue of $17.3m for the quarter exceeds the annualized revenue rate necessary to meet the forecasted $58m in annual revenue by 17%
-- The net income reflects non-cash charges for depreciation, amortization and deferred compensation expense totaling $445,605
-- Cash flow from operations in first quarter 2006, before adjustments to assets and liabilities
I'm completely out of KSW.I didn't like the div 'idea the market'd see as if they can't expand growth .For a small company i think they should put their $$$ to good use like expand their growth .
KSWW-I sold some in the 5.9-6 and still have a lot left .The news is good it just need to consolidate a little bit after the big run.IMO
SMTX -Check this out.
I have to agree with him.I'm in for 5K 2.9 for now and will more after earnings.
SMTX $12 TARGET BEST BUY ON NASDAQ
by: panalta2000
Long-Term Sentiment: Strong Buy 05/05/06 01:39 pm
Msg: 19341 of 19351
-----
The EMS sector will be hot with the SANM results. Look for SMTX to blow through $3.50 resistance before earnings on its way to $12.
SMTX is trading at a RIDICULOUS 2.5 x annualized $13 MM EBITDA (Q4 EBITDA of $3.2 MM).
Last quarter SMTX achieved 7 MM operating cash flow, reduced debt from $30 million to $23 million. Most tech companies trade at 12 x EBITDA SMTX fair value is $12 minimum.
SMTX has only 14 Million shares outstanding and will move up fast, and based on pure financial metrics is the best buy on NASDAQ.
My experience has been that companies that trade at such ridiculous discounts do not remain independent for long.
PTSC .95 now.
It got way ahead of itself.
I shorted CMT 2000 shares @ 7.8.
VVUS
VIVUS Announces Positive Phase 3 Clinical Trial Results for Evamist(TM) - The First Transdermal Spray for the Treatment of Menopausal Symptoms
PR Newswire - May 05, 2006 08:01
Evamist, First Novel Transdermal Spray, Shows 78% Decrease in Moderate to Severe Hot Flashes
MOUNTAIN VIEW, Calif., May 5, 2006 /PRNewswire-FirstCall via COMTEX/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from the pivotal Phase 3 clinical trial of Evamist(TM). VIVUS' investigational estradiol metered dose transdermal spray is being developed for the treatment of vasomotor symptoms associated with menopause. The study showed a statistically significant reduction in the number and severity of moderate and severe hot flashes for all three doses tested. Evamist is a novel, once a day proprietary, first-in-class, transdermal spray that delivers estradiol, a naturally occurring estrogen, for the treatment of hot flashes in women. Evamist is a small, hand-held, simple-to-use spray that is designed to provide an easy and convenient means to deliver a preset dose of estradiol via the skin. Evamist is fast drying, non-irritating and invisible after application. Studies have shown that once administered, Evamist's formulation is not affected by washing and does not transfer to partners. Evamist is easily titratable between one, two or three sprays.
VIVUS' Phase 3 study assessed the safety and efficacy of Evamist for the treatment of hot flashes in menopausal women. The Phase 3 trial, which was conducted at 43 clinical sites in the United States, was a 12-week, randomized, double-blind, placebo controlled study of 457 menopausal women. Patients were randomized into three treatment arms each administering a different dose with one, two or three sprays. This study was conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA). Results showed that the most effective Evamist dose significantly decreased the number of hot flashes by 78%, from 10.7 hot flashes per day at baseline to 2.3 hot flashes after treatment. This decrease was statistically significant compared to placebo (p<0.0001). The reduction in frequency and severity of moderate to severe hot flashes was statistically significant over placebo for all three doses of Evamist evaluated. Importantly, application site irritation was less than 1% and was mild in nature.
"We believe these positive trial results along with our novel patient-preferred transdermal delivery system will establish Evamist as a superior estrogen therapy for the treatment of menopausal symptoms," stated Leland F. Wilson, president and chief executive officer for VIVUS. "We have worked diligently toward the development of this unique and easy-to-use product, and we are thrilled with the efficacy and safety demonstrated in this trial. We now look forward to filing an NDA for Evamist in the second half of 2006."
"These clinical results demonstrate Evamist's efficacy as a treatment option for the large population of women suffering from menopausal symptoms," stated Dr. John Buster, Professor, Baylor College of Medicine. "Symptoms of menopause can be devastating and debilitating. This data indicates that Evamist offers a valuable therapeutic option to this significant patient group."
MZT back to 1.34 .
Not enough vol .I'll pass too.
I'm reloading PTSC here .90
Yep it's weird.
Np and TY
INB ,AEY, CMT -Hotuna- Check out these too.I have boat load of them,
INB accelerate earnings ,AEY PE 10 and CMT (blow out earnings pe less than 9 .
they all have very low OS/float >
CMT shorts squeeze..
Core Molding Technologies Reports First Quarter 2006 Results
PR Newswire - May 04, 2006 09:30
COLUMBUS, Ohio, May 4, 2006 /PRNewswire-FirstCall via COMTEX/ -- Core Molding Technologies, Inc. (Amex: CMT) today announced results for the first quarter ended March 31, 2006.
Net income for the quarter was $2,282,000, or $.23 per basic and $.22 per diluted share, compared with net income of $1,956,000, or $.20 per basic share and diluted share, in the first quarter of 2005. Total net sales for the first quarter of 2006 were $36,502,000, compared with $32,517,000 in the same quarter of 2005. The Company's product sales increased 17% to $35,355,000, from $30,217,000, for the similar period in 2005 primarily due to the addition of the Batavia, Ohio operation, which was acquired in August 2005.
"We are pleased with the results of our first quarter," said James L. Simonton, president and chief executive officer. "We have continued to focus on improving our operations and moving forward our strategic initiatives for growth. Our Batavia operation is beginning to show improvement and we will continue to focus on this operation over the balance of the year. We are also on plan with our previously announced $4.6 million expansion of our Columbus facility in preparation for new products, which are expected to launch in 2007."
Core Molding Technologies, Inc. is a compounder of sheet molding composites (SMC) and molder of fiberglass reinforced plastics. The Company's processing capabilities include the compression molding of SMC, resin transfer molding, multiple insert tooling (MIT), resin transfer molding, spray up and hand lay up processes. The Company produces high quality fiberglass reinforced, molded products and SMC materials for varied markets, including light, medium and heavy-duty trucks, automobiles, automobile aftermarket, personal watercraft and other commercial products. Core Molding Technologies, with its headquarters in Columbus, Ohio, operates plants in Columbus, Batavia, Ohio, Gaffney, South Carolina, and Matamoros, Mexico.
This press release contains certain forward-looking statements within the meaning of the federal securities laws. As a general matter, forward-looking statements are those focused upon future plans, objectives or performance as opposed to historical items and include statements of anticipated events or trends and expectations and beliefs relating to matters not historical in nature. Such forward-looking statements involve known and unknown risks and are subject to uncertainties and factors relating to Core Molding Technologies' operations and business environment, all of which are difficult to predict and many of which are beyond Core Molding Technologies' control. These uncertainties and factors could cause Core Molding Technologies' actual results to differ materially from those matters expressed in or implied by such forward-looking statements.
Core Molding Technologies believes that the following factors, among others, could affect its future performance and cause actual results to differ materially from those expressed or implied by forward-looking statements made in this quarterly report: business conditions in the plastics, transportation, watercraft and commercial product industries; general economic conditions in the markets in which Core Molding Technologies operates; dependence upon four major customers as the primary source of Core Molding Technologies' sales revenues; recent efforts of Core Molding Technologies to expand its customer base; failure of Core Molding Technologies' suppliers to perform their contractual obligations; the availability of raw materials; inflationary pressures; new technologies; competitive and regulatory matters; labor relations; the loss or inability of Core Molding Technologies to attract key personnel; the availability of capital; the ability of Core Molding Technologies to provide on-time delivery to customers, which may require additional shipping expenses to ensure on-time delivery or otherwise result in late fees; risk of cancellation or rescheduling of orders; management's decision to pursue new products or businesses which involve additional costs, risks or capital expenditures; and other risks identified from time-to-time in Core Molding Technologies other public documents on file with the Securities and Exchange Commission, including those described in Item 1A of the 2005 Annual Report to Shareholders on Form 10-K.
CORE MOLDING TECHNOLOGIES, INC.
Condensed Income Statement
(in thousands, except per share data)
Three Months Ended
03/31/06 03/31/05
(Unaudited) (Unaudited)
Product Sales $35,355 $30,218
Tooling Sales 1,147 2,299
Net Sales 36,502 32,517
Cost of Sales 29,674 26,116
Gross Margin 6,828 6,401
Selling, General and Admin. Expense 3,176 3,086
Operating Income 3,652 3,315
Interest Expense - Net 39 173
Income before Taxes 3,613 3,142
Income Tax Expense 1,331 1,186
Net Income $2,282 $1,956
Net Income per Common Share
Basic $0.23 $0.20
Diluted $0.22 $0.20
Weighted Average Shares Outstanding:
Basic 10,047 9,781
Diluted 10,591 9,853
Condensed Balance Sheet
(in thousands)
As of As of
03/31/06 12/31/05
(Unaudited)
Assets
Cash $15,053 $9,414
Accounts Receivable 24,137 22,280
Inventories 7,281 7,295
Other Current Assets 4,564 3,913
Property, Plant & Equipment - net 24,499 23,670
Deferred Tax Asset - net 6,127 6,164
Other Assets 1,469 1,485
Total Assets $ 83,130 $ 74,221
Liabilities and Stockholders' Equity
Current Portion of Long-term Debt $1,786 $1,776
Current Portion of Graduated lease
payments and deferred gain 567 567
Accounts Payable 14,650 10,224
Accrued Liabilities and Other 9,678 7,484
Long-term Debt 9,144 9,695
Deferred Long-term Gain and
Graduated Lease Payments 425 567
Post Retirement Benefits Liability 10,238 9,767
Stockholders' Equity 36,642 34,141
Total Liabilities and Stockholders' Equity $ 83,130 $ 74,221
Another bite the dust VPHM dwn 24% .I have an oder @ 8 for the bounce.
NPSP- they filled my order yesterday 2500 @ 5 .
MT-Remember STAA on 12-23 ? here' s some good news again.
STAAR Surgical Receives CE Mark Approval for Preloaded Aspheric Silicone IOL
Thursday May 4, 6:30 am ET
Launch in 21 Countries of World's First Preloaded IOL Injection System to Offer an Aspheric Optic Design Scheduled for May
MONROVIA, Calif., May. 4 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA - News), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced it has received CE Mark approval for its preloaded aspheric silicone IOL (intraocular lens). The approval will allow STAAR to market the aspheric silicone IOL for use in cataract surgery in 21 countries where the CE Mark is accepted. STAAR's preloaded IOLs are not yet approved for use in the U.S.
http://biz.yahoo.com/prnews/060504/sfth047.html?.v=55
CHID 1.05 26%.
I'm in .89 CHID vol is exploding .
I have an order for 2500 @ 5.
NPSP Stop loss kicked in 5.80
NWBT_ Northwest Biotherapeutics to Present Updated Brain Cancer Data at the International Society for Cellular Therapy Annual Meeting
Wednesday May 3, 7:30 am ET
Personalized Brain Cancer Vaccine Continues to Produce Very Promising Results
BOTHELL, Wash., May 3 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB - News) today announced that the company will be presenting updated data from the second Phase I clinical trial on patients who have received DCVax®-Brain, a personalized therapeutic cancer vaccine, at the 12th Annual Meeting of the International Society for Cellular Therapy (ISCT), being held May 4-7, 2006 in Berlin. http://biz.yahoo.com/prnews/060503/sfw019.html?.v=47
HEPH Hollis-Eden Announces Filing of IND for Phase I Clinical Trials with NEUMUNE in Patients at Risk of Hospital-Acquired Infections
Wednesday May 3, 7:00 am ET
SAN DIEGO--(BUSINESS WIRE)--May 3, 2006--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH - News) today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin Phase I clinical trials with NEUMUNE(TM) (HE2100) in patients at high risk of developing hospital-acquired infections. The purpose of these initial trials will be to establish the safety of NEUMUNE in this population, and to help identify the optimal patient subsets for further study in Phase II efficacy trials. NEUMUNE is already the subject of an open IND for use in treating Acute Radiation Syndrome (ARS), a condition that can increase an individual's susceptibility to life-threatening infections and risk of bleeding.
NWO ,I will only play the bounce @ 5.97.
Watch NPSP for the bounce gap dwn 23% .
It ran out of juice.I think it will close in the red today.IMO
Gap up 5.49/5.5
KSWW is has been on fire and will be on AMEX tomorrow under symbol KSW.
One word "FUTURE"
CombiMatrix to Collaborate with the Washington Animal Disease Diagnostic Laboratory (WADDL) on USA's National Early Detection System for Avian Influenza
Business Wire - May 02, 2006 06:00
WADDL is One of Approximately 48 Labs in the U.S. That is Certified for Influenza Testing
NEWPORT BEACH, Calif., May 02, 2006 (BUSINESS WIRE) -- Acacia Research Corporation (Nasdaq:CBMX)(Nasdaq:ACTG) announced today that its CombiMatrix group will collaborate with the Washington Animal Disease Diagnostic Laboratory (WADDL) on influenza testing. A broad interagency effort is being undertaken to monitor the Pacific Flyway, to determine if the seasonal migration of birds will bring the highly pathogenic Eurasian strain of Avian Influenza (AI: H5N1) into North America and the United States. This effort is being coordinated by the US Department of Agriculture, Department of the Interior, and the Department of Health and Human Services in collaboration with State regulatory agencies.
The Pacific Flyway includes Alaska, Western Canada, and the West Coast of the United States including Washington State. There is concern that the seasonal migration of birds will bring the pathogenic Eurasian H5N1 avian flu into this region of the world through the Pacific Flyway.
The current validated protocol for verification of a pathogenic influenza strain requires performing an initial PCR (polymerase chain reaction) to determine the existence of matrix protein gene, which is common to all Influenza A infections. If matrix protein is present, then a successive PCR for hemagglutinin is performed to determine if the H5 gene is also present. While this part of the procedure can be completed quickly, verification and further typing after a positive result requires that the sample be cultured and sequenced, necessitating roughly another week or more to complete. CombiMatrix's influenza monitoring system has shown in laboratory tests that it can confirm and type the infection in four hours. Our goal in this study is to demonstrate that our system produces quick virus typing results in the diagnostic laboratory environment that correlate to the standard protocol.
"Our Influenza Surveillance Technology has been validated in our laboratory in collaboration with the World Health Organization. We now seek to validate the system in the field in collaboration with WADDL," stated Dr. Amit Kumar, President and CEO of CombiMatrix Corporation. "We are pleased that two Washington State organizations can function together to address this potential animal and public health concern."
"We look forward to working with CombiMatrix to determine if their technology can enable more rapid typing of influenza viruses from animals," said Dr. Terry McElwain, DVM, Ph.D., Professor and Executive Director of WADDL, and Director of Animal Health Research Center at the College of Veterinary Medicine, Washington State University. "While official verification of a highly pathogenic strain of influenza will require virus isolation initially, completing a test that can type the virus in four hours would be a significant advance over the conventional approach in monitoring spread of infection once an outbreak has been confirmed."
It looks good.TY